Compare LGIH & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | CDNA |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.3M | 1.0B |
| IPO Year | 2013 | 2007 |
| Metric | LGIH | CDNA |
|---|---|---|
| Price | $41.81 | $17.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $75.90 | $27.33 |
| AVG Volume (30 Days) | 393.6K | ★ 535.4K |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $1,705,504,000.00 | $48,324,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.33 | $11.23 |
| P/E Ratio | $13.37 | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $39.70 | $10.96 |
| 52 Week High | $74.84 | $21.49 |
| Indicator | LGIH | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 28.72 | 40.44 |
| Support Level | $41.82 | $16.74 |
| Resistance Level | $55.90 | $20.94 |
| Average True Range (ATR) | 1.88 | 0.80 |
| MACD | -1.00 | -0.16 |
| Stochastic Oscillator | 16.85 | 34.48 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.